Introduction: By increasing the number of effective treatments, mania is still remains a challenging problem for health systems. The aim of this study was to compare the efficacy of risperidone and aripiprazole in combination with sodium valproate in bipolar patients with acute manic or mixed episodes who were hospitalized in Razi Psychiatric Hospital in Tehran. Methods: This study was conducted as a double-blind randomized clinical trial in two groups of bipolar disorder patients with manic or mixed episodes (age rage, 18-65 years). The patients were randomly categorized into two groups who received valproate with aripiprazole or risperidone. The clinical response was assessed by the Young mania rating scale and weight gain within 3 and 6 weeks. Data were analyzed using the Chi-square test, paired t-test and analysis of covariance and repeated measures. Results: The study participants had no significant difference in demographic characteristics. Evaluation of the treatment response after 3 and 6 weeks (50% reduction in the Young's scale) in both groups showed no significant difference between the two therapeutic combinations. The combination of sodium valproate and risperidone showed higher weight gain in comparison with the combination of valproate and aripiprazole at the end of the week 6 (P < 0.001). Conclusions: The mentioned therapeutic combinations in the bipolar I disorder with a manic or mixed episode have a similar therapeutic effect. Also, there was no significant difference in their efficacy and both treatments can be used. However, due to the less weight gain, the combination of valproate and aripiprazole is recommended as a safer and more effective therapy in patients who were prone to weight gain.
Today, despite of the improvement in the psychological therapeutic approach, mania still remains as a challenging problem for health system. The aim of this study is comparison efficacy of risperidone and aripiprazole in combination with sodium valproate in bipolar patients with acute manic or mixed episodes who hospitalized in Razi psychiatric hospital in Tehran. This study was conducted as a double blind randomized clinical trial in two groups of bipolar disorder patients with manic or mixed episodes (18–65 age). Patients randomly set in two groups who received valproate with aripiprazole or risperidone. Clinical response was assessed with young mania rating scale (YMRS) and weight gain at 3 and 6 weeks. Data was analyzed with Chi2 test, paired t-test and analysis of covariance and repeated measurement. Evaluation of treatment response after 3 and 6 weeks (50% reduction in Young's scale) in both groups did not show any significant difference between the two therapeutic combinations. The combination of sodium valproate and risperidone showed higher weight gain in comparison with the combination of valproate and aripiprazole at the end of week 6 (P < 0.001). The mentioned combination in bipolar I disorder with manic or mixed episode has similar therapeutic effect, so that both of them are effective and usable. There was no difference in their efficacy, and both treatments can be used. Due to the less weight gain, the combination of valproate and aripiprazole in patients who prone to weight gain, this approach is recommended as more safe and effective therapy.Disclosure of interestThe authors have not supplied their declaration of competing interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.